Recent developments in the management of detrusor overactivity

Vivek Kumar, Lucy Templeman, Christopher R. Chapple, Russell Chess-Williams

Research output: Contribution to journalReview articleResearchpeer-review

40 Citations (Scopus)

Abstract

Purpose of review: Detrusor overactivity is a relatively common yet embarrassing symptom complex with significant impact on quality of life. The mainstay of current pharmacological treatment involves use of muscarinic receptor antagonists, but their therapeutic efficacy is limited by their troublesome side effects resulting in the non-continuance of treatment in a significant number of patients. Therefore, the development of new drugs can proceed by targeting alternative pathways affecting detrusor overactivity. In this article, the pharmacological basis for the current therapeutic alternatives for managing detrusor overactivity and possible future developments are discussed. Recent findings: It is clear that far from being a passive container for urine, the urothelium is a crucial part of the bladder. Its functions are complex, dynamic and important, and only now becoming understood. The release of ATP from urothelium in response to distension and its action on P2X receptors resulting in activating both motor and sensory neurons is being increasingly recognised. In the normal bladder, muscarinic receptor stimulation produces the main part of detrusor contraction. However, in functionally abnormal bladders, a non-cholinergic activation via the purinergic receptors may occur. The central nervous mechanisms controlling the micturition reflex have also recently attracted attention. Summary: Recent research has suggested that several transmitters may modulate voiding. However, few drugs with clinical benefits have been developed so far. Present treatments for overactive bladders have significant non-compliance rates. Hopefully, future research will lead to drugs with greater therapeutic benefits and better tolerance.

Original languageEnglish
Pages (from-to)285-291
Number of pages7
JournalCurrent Opinion in Urology
Volume13
Issue number4
DOIs
Publication statusPublished - Jul 2003
Externally publishedYes

Fingerprint

Urothelium
Urinary Bladder
Muscarinic Receptors
Therapeutics
Pharmaceutical Preparations
Pharmacology
Purinergic Receptors
Overactive Urinary Bladder
Muscarinic Antagonists
Urination
Motor Neurons
Sensory Receptor Cells
Reflex
Adenosine Triphosphate
Quality of Life
Urine
Research

Cite this

Kumar, Vivek ; Templeman, Lucy ; Chapple, Christopher R. ; Chess-Williams, Russell. / Recent developments in the management of detrusor overactivity. In: Current Opinion in Urology. 2003 ; Vol. 13, No. 4. pp. 285-291.
@article{106ff6fa1bc6481285df8f64a9ac6a8f,
title = "Recent developments in the management of detrusor overactivity",
abstract = "Purpose of review: Detrusor overactivity is a relatively common yet embarrassing symptom complex with significant impact on quality of life. The mainstay of current pharmacological treatment involves use of muscarinic receptor antagonists, but their therapeutic efficacy is limited by their troublesome side effects resulting in the non-continuance of treatment in a significant number of patients. Therefore, the development of new drugs can proceed by targeting alternative pathways affecting detrusor overactivity. In this article, the pharmacological basis for the current therapeutic alternatives for managing detrusor overactivity and possible future developments are discussed. Recent findings: It is clear that far from being a passive container for urine, the urothelium is a crucial part of the bladder. Its functions are complex, dynamic and important, and only now becoming understood. The release of ATP from urothelium in response to distension and its action on P2X receptors resulting in activating both motor and sensory neurons is being increasingly recognised. In the normal bladder, muscarinic receptor stimulation produces the main part of detrusor contraction. However, in functionally abnormal bladders, a non-cholinergic activation via the purinergic receptors may occur. The central nervous mechanisms controlling the micturition reflex have also recently attracted attention. Summary: Recent research has suggested that several transmitters may modulate voiding. However, few drugs with clinical benefits have been developed so far. Present treatments for overactive bladders have significant non-compliance rates. Hopefully, future research will lead to drugs with greater therapeutic benefits and better tolerance.",
author = "Vivek Kumar and Lucy Templeman and Chapple, {Christopher R.} and Russell Chess-Williams",
year = "2003",
month = "7",
doi = "10.1097/00042307-200307000-00004",
language = "English",
volume = "13",
pages = "285--291",
journal = "Current Opinion in Urology",
issn = "0963-0643",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

Recent developments in the management of detrusor overactivity. / Kumar, Vivek; Templeman, Lucy; Chapple, Christopher R.; Chess-Williams, Russell.

In: Current Opinion in Urology, Vol. 13, No. 4, 07.2003, p. 285-291.

Research output: Contribution to journalReview articleResearchpeer-review

TY - JOUR

T1 - Recent developments in the management of detrusor overactivity

AU - Kumar, Vivek

AU - Templeman, Lucy

AU - Chapple, Christopher R.

AU - Chess-Williams, Russell

PY - 2003/7

Y1 - 2003/7

N2 - Purpose of review: Detrusor overactivity is a relatively common yet embarrassing symptom complex with significant impact on quality of life. The mainstay of current pharmacological treatment involves use of muscarinic receptor antagonists, but their therapeutic efficacy is limited by their troublesome side effects resulting in the non-continuance of treatment in a significant number of patients. Therefore, the development of new drugs can proceed by targeting alternative pathways affecting detrusor overactivity. In this article, the pharmacological basis for the current therapeutic alternatives for managing detrusor overactivity and possible future developments are discussed. Recent findings: It is clear that far from being a passive container for urine, the urothelium is a crucial part of the bladder. Its functions are complex, dynamic and important, and only now becoming understood. The release of ATP from urothelium in response to distension and its action on P2X receptors resulting in activating both motor and sensory neurons is being increasingly recognised. In the normal bladder, muscarinic receptor stimulation produces the main part of detrusor contraction. However, in functionally abnormal bladders, a non-cholinergic activation via the purinergic receptors may occur. The central nervous mechanisms controlling the micturition reflex have also recently attracted attention. Summary: Recent research has suggested that several transmitters may modulate voiding. However, few drugs with clinical benefits have been developed so far. Present treatments for overactive bladders have significant non-compliance rates. Hopefully, future research will lead to drugs with greater therapeutic benefits and better tolerance.

AB - Purpose of review: Detrusor overactivity is a relatively common yet embarrassing symptom complex with significant impact on quality of life. The mainstay of current pharmacological treatment involves use of muscarinic receptor antagonists, but their therapeutic efficacy is limited by their troublesome side effects resulting in the non-continuance of treatment in a significant number of patients. Therefore, the development of new drugs can proceed by targeting alternative pathways affecting detrusor overactivity. In this article, the pharmacological basis for the current therapeutic alternatives for managing detrusor overactivity and possible future developments are discussed. Recent findings: It is clear that far from being a passive container for urine, the urothelium is a crucial part of the bladder. Its functions are complex, dynamic and important, and only now becoming understood. The release of ATP from urothelium in response to distension and its action on P2X receptors resulting in activating both motor and sensory neurons is being increasingly recognised. In the normal bladder, muscarinic receptor stimulation produces the main part of detrusor contraction. However, in functionally abnormal bladders, a non-cholinergic activation via the purinergic receptors may occur. The central nervous mechanisms controlling the micturition reflex have also recently attracted attention. Summary: Recent research has suggested that several transmitters may modulate voiding. However, few drugs with clinical benefits have been developed so far. Present treatments for overactive bladders have significant non-compliance rates. Hopefully, future research will lead to drugs with greater therapeutic benefits and better tolerance.

UR - http://www.scopus.com/inward/record.url?scp=0042868718&partnerID=8YFLogxK

U2 - 10.1097/00042307-200307000-00004

DO - 10.1097/00042307-200307000-00004

M3 - Review article

VL - 13

SP - 285

EP - 291

JO - Current Opinion in Urology

JF - Current Opinion in Urology

SN - 0963-0643

IS - 4

ER -